VPDL Chemotherapy for T-cell Lymphoblastic Lymphoma (T-LBL) in Adults: Comparison with Upfront Autologous Stem Cell Transplantation in a Single Center.
10.5045/kjh.2008.43.3.138
- Author:
Dok Hyun YOON
1
;
Byeong Seok SOHN
;
Wook Jin LEE
;
Sung Nam LIM
;
Eun Kyoung KIM
;
Inkeun PARK
;
Kyong Min KIM
;
Geundoo JANG
;
Shin KIM
;
Dae Ho LEE
;
Jooryung HUH
;
Cheolwon SUH
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. csuh@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
T-cell lymphoblastic lymphoma;
Chemotherapy and autologous stem cell transplantation
- MeSH:
Adult;
Disease-Free Survival;
Follow-Up Studies;
Humans;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
Retrospective Studies;
Stem Cell Transplantation;
Stem Cells;
T-Lymphocytes
- From:Korean Journal of Hematology
2008;43(3):138-144
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Treatment of T-cell lymphoblastic lymphoma (T-LBL) with CHOP or CHOP-like chemotherapy has resulted in poor long-term outcomes. High-dose chemotherapy followed by ASCT has been applied for this dreaded disease. However, the efficacy is still controversial. T-LBL is considered the nodal/extranodal presentation of acute lymphoblastic leukemia. Favorable results with VPDL chemotherapy have been reported in the setting of adult lymphoblastic leukemia. We, therefore, treated T-LBL patients with modified VPDL chemotherapy and compared the outcomes with those achieved using upfront ASCT. METHODS: We retrospectively reviewed the outcomes of 24 T-LBL patients treated either with upfront ASCT (n=11) or VPDL chemotherapy without ASCT (n=13) between January 1996 and October 2005. RESULTS: The median follow-up duration for surviving patients was 17 months (range, 5~109 months). The two-year event-free survival (EFS) rates were 83.1% in the VPDL group and 27.3% in the upfront ASCT group (P=0.008). The two-year overall survival (OS) rates were 83.9% in the VPDL group and 27.3% in the upfront ASCT group (P=0.006). CONCLUSION: This study suggests that VPDL chemotherapy is very effective and may be superior to upfront ASCT in the treatment of T-LBL patients.
